Edition:
United Kingdom

Innoviva Inc (INVA.OQ)

INVA.OQ on NASDAQ Stock Exchange Global Select Market

19.67USD
18 Jan 2019
Change (% chg)

$0.20 (+1.03%)
Prev Close
$19.47
Open
$19.54
Day's High
$19.81
Day's Low
$19.48
Volume
186,902
Avg. Vol
293,527
52-wk High
$19.81
52-wk Low
$13.27

Latest Key Developments (Source: Significant Developments)

Theravance Biopharma Highlights Expanded COPD Indication For Trelegy Ellipta In Europe
Monday, 12 Nov 2018 

Nov 12 (Reuters) - Theravance Biopharma Inc ::THERAVANCE BIOPHARMA HIGHLIGHTS EXPANDED COPD INDICATION FOR TRELEGY ELLIPTA IN EUROPE.THERAVANCE BIOPHARMA INC - EUROPEAN COMMISSION AUTHORIZED AN EXPANDED LABEL FOR ONCE-DAILY TRELEGY ELLIPTA.  Full Article

Innoviva Reports Q3 EPS Of $0.43
Wednesday, 31 Oct 2018 

Oct 31 (Reuters) - Innoviva Inc ::INNOVIVA REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 EARNINGS PER SHARE $0.43.Q3 REVENUE ROSE 26.8 PERCENT TO $61.7 MILLION.  Full Article

GSK Says CHMP Recommends Expansion Of Trelegy COPD Label
Friday, 21 Sep 2018 

Sept 21 (Reuters) - GlaxoSmithKline PLC ::GLAXOSMITHKLINE PLC - CHMP RECOMMENDS EXPANSION OF TRELEGY COPD LABEL.GLAXOSMITHKLINE PLC - EMA COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) HAS ISSUED A POSITIVE OPINION TODAY SUPPORTING USE OF TRELEGY ELLIPTA.  Full Article

Innoviva Q2 Earnings Per Share $0.49
Thursday, 26 Jul 2018 

Innoviva Inc ::INNOVIVA REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 EARNINGS PER SHARE $0.49.Q2 REVENUE ROSE 14.6 PERCENT TO $67.1 MILLION.  Full Article

Glaxosmithkline Says FDA Approves Expanded Indication For Trelegy Ellipta In The U.S.
Tuesday, 24 Apr 2018 

April 24 (Reuters) - GlaxoSmithKline ::FDA APPROVED EXPANDED INDICATION FOR TRELEGY ELLIPTA IN THE U.S. FOR TREATMENT OF PATIENTS WITH COPD.  Full Article

GSK and Innoviva announce positive data from COPD study
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Glaxosmithkline Plc :GSK STUDY DEMONSTRATES SUPERIORITY OF ANORO ELLIPTA TO STIOLTO RESPIMAT IN IMPROVING LUNG FUNCTION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE.GSK - ‍POSITIVE DATA FROM A STUDY COMPARING A ONCE-DAILY LAMA AND LABA FIXED-DOSE COMBINATION, ANORO ELLIPTA AND STIOLTO RESPIMAT FOR COPD​.GSK - ‍ENDPOINT WAS MET, AND UMEC/VI DEMONSTRATED SUPERIORITY TO TIO/OLO, WITH A DIFFERENCE IN TREATMENT EFFECT OF 52ML ON TROUGH FEV1 AT WEEK EIGHT ​.GLAXOSMITHKLINE PLC - ‍MOST FREQUENTLY-REPORTED ADVERSE EVENTS WERE UPPER RESPIRATORY TRACT INFECTIONS, COUGH AND DIARRHOEA​.GLAXOSMITHKLINE PLC - ‍BOTH TREATMENTS DEMONSTRATED A COMPARABLE TOLERABILITY AND SAFETY PROFILE​.GLAXOSMITHKLINE PLC - ‍OVERALL INCIDENCE OF ON-TREATMENT ADVERSE EVENTS OF 25% IN UMEC/VI GROUP AND 31% IN TIO/OLO GROUP​.  Full Article

Innoviva reports Q3 adj earnings $0.31/shr
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Innoviva Inc :Innoviva reports third quarter 2017 financial results and provides business updates.Q3 adjusted earnings per share $0.31.Q3 earnings per share view $0.31 -- Thomson Reuters I/B/E/S.Innoviva Inc - ‍plans to repurchase up to $80 million of common stock, pursuant to an accelerated share repurchase (ASR) plan​.Innoviva Inc - qtrly ‍total revenue $48.6 million versus $33.3 million.Q3 revenue view $57.2 million -- Thomson Reuters I/B/E/S.  Full Article